Fennec Pharmaceuticals

FENC

Valor de mercado US$ 350 mi

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~

The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Investors need to pay close attention to FENC stock based on the movements in the options market lately.

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.